Links to Benzodiazepines Teaching Resources



  • Alprazolam1
  • Bentazepam
  • Bromazepam
  • Brotizolam
  • Chlordiazepoxide
  • Clobazam
  • Clonazepam
  • Clorazepate1
  • Delorazepam
  • Diazepam
  • Estazolam
  • Flunitrazepam
  • Flurazepam
  • Halazepam
  • Ketazolam
  • Loprazolam
  • Lorazepam
  • Lormetazepam
  • Medazepam
  • Metaclazepam
  • Midazolam
  • Nitrazepam
  • Oxazepam
  • Pinazepam
  • Prazepam
  • Quazepam
  • Temazepam
  • Tetrazepam
  • Triazolam
Benzodiazepine-like drugs also discussed here:
  • Zaleplon
  • Zolpidem
  • Zopiclone
1 Modified release preparation marketed in some countries


Benzodiazepines are sedating drugs, which do not usually cause either profound CNS or respiratory depression or any non-sedative effects. Deaths may occur prior to hospital due to sedation (particularly if combined with other sedative drugs e.g., alcohol) but the course of patients reaching hospital is generally uncomplicated. Zaleplon, zolpidem and zopiclone are not benzodiazepines but have similar toxicity in overdose and bind to the BZ1 receptor subtype of the benzodiazepine receptor adjacent to the GABA-A receptor in the central nervous system. Diazepam and many of the others are regularly abused. Street names for diazepam include: Benzo; Black pearl; Blue; Blue bombers; Blue boys; Blue magoos; Blue thunder; Blues; Drunk pills; La Roche; Ludes; Mother's little helper; Mother's little helpers; Pami; Roaches; Roachies; Roche; V; Vs blues; Valleys; Vallies; Vals.


Benzodiazepines bind to the benzodiazepine receptor, which modifies the gamma amino benzoic acid (GABA) chloride channel complex. Benzodiazepines enhance the effects of GABA. GABA is an inhibitory neurotransmitter and thus central nervous system depression occurs. Benzodiazepines also cause muscle relaxation and are anticonvulsant. Zaleplon, zolpidem and zopiclone cause sedation but have little muscle relaxant or anticonvulsant properties.

The GABA(A) receptor-benzodiazepine receptor-chloride ion channel complex is not homogenous and can be assembled from multiple different combinations of alpha, beta and gamma sub-units. Zolpidem is a potent agonist at GABA(A) receptors but only those containing the alpha1 subunit (corresponding to the benzodiazepine (BZ)1 or omega1 subtype); it is not effective at receptors containing the alpha5 subunit (corresponding to one type of BZ2 or omega2 receptors). It is this selectivity for BZ1 receptors that is thought to explain its greater potency as a sedative-hypnotic and lesser activity as a muscle relaxant and anticonvulsant. The sedative-hypnotic effects are antagonised by flumazenil. It has been proposed that zolpidem lacks benzodiazepine-like side-effects, having minimal abuse and dependence potential. Nevertheless, there are a considerable number of zolpidem dependence case reports in the literature and a withdrawal syndrome including seizures exists. Zolpidem has recently been classified as a psychotropic at risk of abuse in Europe.

Zopiclone is a potent agonist at binding sites that belong to the GABA(A) receptor-benzodiazepine receptor-chloride ion channel complex but which are not the benzodiazepine specific sites. The GABA(A) receptor-benzodiazepine receptor-chloride ion channel complex is discussed in the benzodiazepine monograph. Zopiclone either acts on a site distinct from that of benzodiazepines or induces conformational changes different from those induced by benzodiazepines. It is possible that zopiclone acts via the mitochondrial benzodiazepine receptor which can result in allosteric modulation of GABA(A) receptor function. Zopiclone has no effect on other brain receptors such as the GABA receptor itself, dopamine receptors, serotonin or noradrenergic receptors. The sedative-hypnotic effects are antagonized by flumazenil. As with zolpidem, initial suggestions were that there was little or no potential for tolerance, abuse or dependence, however, it is clear that all can occur and that a withdrawal syndrome including delirium exists.



All benzodiazepines are lipid soluble drugs that are absorbed fairly rapidly. The rate of absorption is an important variable in determining the clinical effects of benzodiazepines. Rapid rises in serum concentrations lead to greater depth of sedation than slow rises to the same concentrations. The most rapidly absorbed drugs are temazepam and flurazepam and less rapidly absorbed drugs include oxazepam. The extent of absorption of these drugs is high


All these drugs are highly protein bound and have volumes of distributions of about 1 L/kg. They distribute well into the central nervous system.

Metabolism - Elimination

All benzodiazepines are hepatically metabolised with renal clearance accounting for less than 5%. The half-life of these drugs varies widely and a number of drugs have active metabolites. Drug with a shorter half-life (temazepam, triazolam) and drugs with a longer half-life (diazepam, clonazepam) still have very similar spectrums of clinical toxicity. This is due to the development of tolerance to the effects of benzodiazepines. It is actually the development of tolerance to the benzodiazepines that determines the recovery of consciousness rather than the clearance of the drug.

After a single 20 mg oral dose peak plasma concentrations of 0.192 to 0.324 mg/L occur 0.75 to 2.6 hours post dose. Zolpidem was identified in the blood of 29 subjects arrested for impaired driving. Zolpidem concentrations ranged from 0.05 to 1.4 mg/L (mean 0.29 mg/L). In the subjects where zolpidem was present with other drugs and/or alcohol, symptoms reported included slow movements and reactions, slow and slurred speech, poor coordination, lack of balance, flaccid muscle tone, and horizontal and vertical gaze nystagmus. In five separate cases, where zolpidem was the only drug detected (0.08–1.40 mg/L, mean 0.65 mg/L), signs of impairment included slow and slurred speech, slow reflexes, disorientation, lack of balance and coordination, and "blacking out". After ingestion of 300 mg of zolpidem, an initial plasma concentration of > 0.5 mg/L was reported in a comatose patient.

The disposition of the enantiomers of zopiclone was investigated after oral administration of a single dose of 15 mg of a racemic mixture (twice the usual therapeutic dose) in 12 adult Caucasian volunteers. Determination of concentrations of zopiclone enantiomers in plasma showed that zopiclone pharmacokinetics is stereoselective with peak concentrations of 0.0873 and 0.044 mg/L for (+)-zopiclone and (-)-zopiclone, respectively.
After zopiclone 7.5 mg, alcohol enhanced and prolonged the effects without modifying plasma concentration. After oral ingestion of 300 mg of zopiclone, the plasma concentration was 1.6 mg/L at 4.5 hours after the dose and the elimination half-life was 3.5 hours.


The clinical effects of benzodiazepine poisoning are due entirely to central nervous system depression. Severe poisonings may develop hypothermia, bradycardia, and hypotension, however this is unusual. Respiratory depression and depression of consciousness may lead to aspiration pneumonia. However, deep coma is unusual. Most patients are stuporous or still responsive to painful stimuli unless they have co-ingested other sedating drugs.

Zolpidem in overdose generally produces mild CNS depression with drowsiness, slow movements and reactions, slow and slurred speech, poor coordination, lack of balance, flaccid muscle tone, and horizontal and vertical gaze nystagmus. Occasionally more severe CNS depression occurs with development of a profound but short-lasting coma, associated with pin-point pupils and respiratory depression especially if other drugs or ethanol are ingested or in cases of chronic hepatic or respiratory insufficiency. Pulmonary oedema occurs in fatal cases.
In a large series of 244 cases of intentional acute overdoses, half of the patients ingested other substances (psychotropic drugs and alcohol) concomitantly. Signs of intoxication were observed in two thirds of the population but could be attributed to zolpidem in only 105 cases with drowsiness, vomiting, coma or respiratory failure. There were no electrocardiographic abnormalities that appeared to be directly related to zolpidem and symptoms of intoxication rapidly remitted in 91% of cases.
In a series of 91 well documented cases of acute zolpidem intoxication there were 54 single-drug poisonings with zolpidem. Of these, only one patient became comatose. On the other hand, in combined intoxications with other CNS active drugs or ethanol, coma was more common even if the amount of the additionally ingested drugs in itself would not have caused a comatose state.
In a series of 12 pediatric zolpidem exposures, in ten cases onset of symptoms was within 10 to 60 min (mean 31.6 min). The duration of symptoms in the unintentional cases ranged from less than 60 min up to 4 hours (mean 2.4 hours) and 6–10 hours (mean 7.5 hours) in the intentional exposures.

Drowsiness, lethargy and ataxia are the principal effects reported in zopiclone overdose. Rarely, coma may occur. In a death due to respiratory failure after zopiclone overdose it was postulated that hypoventilation due CNS depression occurred. Similar to benzodiazepines, coma may be due to flow limitation and obstructive apnoea via an increase in upper airway resistance and work of breathing. There is a single case report of first-degree heart block after zopiclone poisoning.


Rapidly absorbed drugs lead to greater degrees of CNS depression than slowly absorbed drugs. There are differences in fatal toxicity within this class with temazepam and flurazepam having much higher rates of fatal overdose per prescription than other drugs such as oxazepam. This appears to be due to sedation as temazepam has been found more sedating in overdose than oxazepam. However, in a patient who presents with benzodiazepine overdose, these differences do not require any change to management. Zaleplon, zolpidem and zopiclone are not benzodiazepines but have similar toxicity in overdose and bind to the BZ1 receptor subtype of the benzodiazepine receptor adjacent to the GABA-A receptor in the central nervous system.

Zolpidem, in therapeutic doses, has been implicated in psychotic reactions characterized by auditory and visual hallucinations as well as delusional thinking. In a large series (344 cases) of zolpidem overdose in adults, ingested doses of zolpidem ranged between 10 and 1400 mg. Drowsiness occurred at doses of 140 to 440 mg; coma or respiratory failure were rare. In a series of 54 single-drug poisonings with zolpidem in adults, only mild symptoms were observed up to 600 mg. Patients mainly suffered from somnolence. Only one patient became comatose after ingestion of 600 mg zolpidem. On the other hand, in combined intoxications with other CNS active drugs or ethanol a zolpidem dose as low as 100–150 mg induced coma in some patients, even if the amount of the additionally ingested drugs in itself would not have caused a comatose state. In a 44-year old male an overdose of 200 mg of zolpidem alone resulted in coma (GCS of 7) and respiratory failure. In a series of 12 pediatric ingestions, one child had no effect with 2.5 mg. As little as 5 mg caused symptoms with minor outcome in six unintentional ingestions (5–30 mg). Minor to moderate symptoms were reported 1–4 hours after intentional ingestions (12.5–150 mg).

After a therapeutic dose of zopiclone (7.5 mg), alcohol enhanced and prolonged the effect without modifying plasma concentrations.
Transient first degree AV heart block occurred after ingestion of 127.5 mg of zopiclone (in combination with piperazine). Sleepiness was the only feature after an oral ingestion of 300 mg of the drug.
A 72-year-old man being treated for lung cancer ingested 90 mg of zopiclone in a suicide attempt and died between 4 and 10 hours after the ingestion. A combined ingestion of alcohol and 150 mg of zopiclone resulted in the death of a 29-year old woman. A 72-year-old woman with poor respiratory function due to bronchogenic carcinoma died after ingesting 200 to 350 mg of zopiclone.


The severity of sedative drug overdose should be measured using the Glasgow Coma Score, a seven point scale of unconsciousness or the McCarron Score. These all measure the depth of coma and this should be the indication for whether patients require intubation and/or ventilation.


The preferred treatment is entirely supportive with maintenance of the airway and ventilation, IV access and fluids.

GI Decontamination

Oral activated charcoal is of no value in pure benzodiazepine poisoning. It may be given to patients who have recently (within 1 hour) ingested benzodiazepines with other drugs that may benefit from decontamination. Gastric lavage is not indicated.


Flumazenil is a benzodiazepine antagonist. It may be used for either diagnosis or treatment. It also is effective for zaleplon, zolpidem and zopiclone. However, patients are likely to wake from their sedation or coma because of the rapid development of tolerance rather than from clearance of the drug. The administration of a benzodiazepine antagonist such as flumazenil in the presence of a benzodiazepine prevents of the development of tolerance. This could theoretically result in a prolongation of the effect of the benzodiazepine manifesting as a prolonged requirement for the antagonist and hospital length of stay. This has been seen after diazepam overdose treated with flumazenil while, in contrast, a much shorter duration of symptoms was seen with similar doses managed before the availability of an antagonist. For routine management of uncomplicated benzodiazepine, zaleplon, zolpidem or zopiclone overdose there is no indication for the use of flumazenil.

Diagnostic use

Flumazenil (0.1–2.0 mg IV) has been given to unconscious patients where the drug ingested is unknown although this remains controversial. Flumazenil should only be given if there is no evidence of proconvulsant/proarrhythmic drug ingestion as the removal of the effects of benzodiazepines or other similar drugs that have been co-ingested may lead to seizures, cardiac arrest or death.

Contraindications to flumazenil administration

Indications that the patient may have ingested proconvulsant drug include:
  • widened QRS complex on the ECG
  • hyperreflexia and myoclonus
  • anticholinergic signs
  • marked tachycardia
  • hypokalaemia

Elimination enhancement

This is not indicated.


Long term sequelae are unusual and patients usually recover consciousness within twelve hours although the elderly may take considerably longer. Patients who fail to regain consciousness within this time should have a search made for alternative causes of sedation including non-toxicological causes.
Patients with a significant sedative drug overdose should be advised not to drive until potential interference with psychomotor performance has resolved. For overdose of most of these agents this will be at least 48–72 hours after discharge.


Ahmad Z, Herepath M, Ebden P. Diagnostic utility of flumazenil in coma with suspected poisoning. BMJ 1991; 302(6771): 292 PMID1998806
Amrein R1, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesio 1988 ;2 Suppl: 65-80 PMID2842143
Anon. Hypnotic dependence: zolpidem and zopiclone too. Prescrire Int 2001; 10(51): 15 PMID11503851
Anon. Zolpidem: now classified as a psychotropic at risk of abuse. Prescrire Int 2003; 12(64): 60 PMID12674120
Barrero-Hernandez FJ, Ruiz-Veguilla M, Lopez-Lopez MI, Casado-Torres A. [Epileptic seizures as a sign of abstinence from chronic consumption of zolpidem]. Rev Neurol 2002; 34(3): 253–6 PMID12022074
Bramness JG, Arnestad M, Karinen R, Hilberg T. Fatal overdose of zopiclone in an elderly woman with bronchogenic carcinoma. J Forensic Sci 2001; 46(5): 1247–9 PMID11569575
Brown MJ, Bristow DR. Molecular mechanisms of benzodiazepine-induced down-regulation of GABAA receptor alpha 1 subunit protein in rat cerebellar granule cells. Br J Pharmacol 1996; 118(5): 1103–10 PMID8818332
Buckley NA1, Whyte IM, Dawson AH, McManus PR, Ferguson NW. Self-poisoning in Newcastle, 1987-1992. Med J Aust 1995; 162(4): 190-3 PMID7877540
Buckley NA, Whyte IM, Dawson AH, O'Connell D. The relative toxicity of benzodiazepines in overdose. BMJ 1995; 310(6974): 219–21 PMID7866122
Burkhart KK, Kulig KW. The diagnostic utility of flumazenil (a benzodiazepine antagonist) in coma of unknown etiology. Ann Emerg Med 1990; 19(3): 319–21 PMID2106810
Chern TL, Kwan A. Flumazenil-induced seizure accompanying benzodiazepine and baclofen intoxication. Am J Emerg Med 1996; 14(2): 231–2 PMID8924153
Crestani F, Martin JR, Mohler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000; 131(7): 1251–4 PMID11090095
Dassanayake TL, Michie PT, Jones AL, et al. Cognitive skills underlying driving in patients discharged following self-poisoning with central nervous system depressant drugs. Traffic Inj Prev 2012 Sep; 13(5): 450–7 PMID22931174
Debailleul G, Khalil FA, Lheureux P. HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication. J Anal Toxicol 1991; 15(1): 35–37 PMID1675298
Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986; 237(2): 649–58 PMID2871178
de Haro L, Valli M, Bourdon JH, et al. Diazepam poisoning with one-month monitoring of diazepam and nordiazepam blood levels. Vet Hum Toxicol 2001; 43(3): 174–5 PMID11383664
Derlet RW, Albertson TE. Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications. Ann Emerg Med 1994; 23(3): 494–8 PMID8135424
Doble A. New insights into the mechanism of action of hypnotics. J Psychopharmacol 1999; 13(4 Suppl 1): S11–S20 PMID10667451
Dollery CT. Therapeutic drugs. CD_ROM DATABASE Release 1.0 ed. London: Churchill Livingstone, 1999
Fernandez C, Maradeix V, Gimenez F, Thuillier A, Farinotti R. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 1993; 21(6): 1125–8 PMID7905394
Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. Obstet Gynecol 1985; 66(3 Suppl): 34S-35S PMID4022513
Garnier R, Guerault E, Muzard D, et al. Acute zolpidem poisoning–analysis of 344 cases. J Toxicol Clin Toxicol 1994; 32(4): 391–404 PMID 8057398
Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. Drug Saf 1991; 6: 247–65 PMID 1888441
Gock SB, Wong SH, Nuwayhid N, et al. Acute zolpidem overdose--report of two cases. J Anal Toxicol 1999; 23(6): 559–62 PMID 10517569
Greenblatt DJ, Woo E, Allen MD, Orsulak PJ, Shader RI. Rapid recovery from massive diazepam overdose. JAMA 1978; 240(17): 1872–4 PMID 357765
Gueye PN, Hoffman JR, Taboulet P, Vicaut E, Baud FJ. Empiric use of flumazenil in comatose patients: limited applicability of criteria to define low risk. Ann Emerg Med 1996; 27(6): 730–5 PMID 8644960
Gueye PN, Lofaso F, Borron SW, et al. Mechanism of respiratory insufficiency in pure or mixed drug-induced coma involving benzodiazepines. J Toxicol Clin Toxicol 2002; 40(1): 35–47 PMID11990203
Hamad A, Sharma N. Acute zolpidem overdose leading to coma and respiratory failure. Intensive Care Med 2001; 27(7): 1239 PMID 11534578
Harry P. [Acute poisoning by new psychotropic drugs.] Rev Prat 1997; 47(7): 731–5 PMID 9183949
Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother 1994; 28(12): 1347–9 PMID7696723
Herd B, Clarke F. Complete heart block after flumazenil. Hum Exp Toxicol 1991; 10(4): 289 PMID1679653
Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995; 274(7): 562–9 PMID 7629986
Hojer J, Baehrendtz S, Matell G, Gustafsson LL. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomised controlled study. BMJ 1990; 301(6764): 1308–11 PMID1980218
Ingum J, Bjorklund R, Volden R, Morland J. Development of acute tolerance after oral doses of diazepam and flunitrazepam. Psychopharmacol 1994; 113(3–4): 304–10 PMID7862837
Kuitunen T, Mattila MJ, Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol 1990; 5 Suppl 2: 115–130 PMID2201724
Kurta DL, Myers LB, Krenzelok EP. Zolpidem (Ambien): a pediatric case series. J Toxicol Clin Toxicol 1997; 35(5): 453–7 PMID9279301
Lheureux P, Debailleul G, De Witte O, Askenasi R. Zolpidem intoxication mimicking narcotic overdose: response to flumazenil. Hum Exp Toxicol 1990; 9(2): 105–7 PMID2111156
Lheureux P, Vranckx M, Leduc D, Askenasi R. Flumazenil in mixed benzodiazepine/tricyclic antidepressant overdose: a placebo-controlled study in the dog. Am J Emerg Med 1992; 10(3): 184–8 PMID1586424
Liappas IA, Malitas PN, Dimopoulos NP, et al. Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol 2003; 17(1): 131–5 PMID12680751
Logan BK, Couper FJ. Zolpidem and driving impairment. J Forensic Sci 2001; 46(1): 105–10 PMID11210892
Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry 1996; 8(2): 89–91 PMID8807033
Meatherall RC. Zopiclone fatality in a hospitalized patient. J Forensic Sci 1997; 42(2): 340-3 PMID9068198
Meredith TJ, Jacobsen D, Haines JA, Berger J-C (eds). Naloxone, flumazenil and dantrolene as antidotes. IPCS/CEC evaluation of antidotes series Vol 1. Cambridge University Press, 1993
Mordel A, Winkler E, Almog S, Tirosh M, Ezra D. Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care Med 1992; 20(12): 1733–4 PMID1458953
Patat A, Naef MM, van Gessel E, Forster A, Dubruc C, Rosenzweig P. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. Clin Pharmacol Ther 1994; 56(4): 430–6 PMID7955804
Pounder DJ, Davies JI. Zopiclone poisoning: tissue distribution and potential for postmortem diffusion. Forensic Sci Int 1994; 65(3): 177–83 PMID8039775
Regouby Y, Delomez G, Tisserant A. [First-degree heart block caused by voluntary zopiclone poisoning]. Therapie 1990; 45(2): 162 PMID2353332
Rochette A, Le Niger E, Moulins H, Manchon M. [Voluntary drug poisoning: epidemiology, performance and limits of the emergency laboratory.] J Toxicol Clin Exp 1990; 10(6): 395-408 PMID2130183
Royer-Morrot MJ, Rambourg M, Jacob I, Bauer P, Royer RJ. Determination of zopiclone in plasma using column liquid chromatography with ultraviolet detection. J Chromatogr 1992; 581(2): 297–9 PMID1452623
Rudolph U, Crestani F, Mohler H. GABA(A) receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001; 22(4): 188-94 PMID11282419
Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29(3): 142–53 PMID 8521677
Schulze-Bonhage A, Elger CE. Induction of partial epileptic seizures by flumazenil. Epilepsia 2000; 41(2): 186–92 PMID10691115
Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 1993; 163: 386–93 PMID8104653
Short TG, Maling T, Galletly DC. Ventricular arrhythmia precipitated by flumazenil. Br Med J (Clin Res Ed) 1988; 296(6628): 1070-1 PMID3130150
Velvart J. [Epidemiology of acute drug poisoning in Switzerland.] Schweiz Med Wochenschr 1982; 112(31-32): 1101-4 PMID7134935
Weinbroum A, Rudick V, Sorkine P, Fleishon R, Geller E. Long-term intravenous and oral flumazenil treatment of acute diazepam overdose in an older patient. J Am Geriatr Soc 1996; 44(6): 737–8 PMID8642175
Wyss PA, Radovanovic D, Meier-Abt PJ. [Acute overdose of Zolpidem (Stilnox).] Schweiz Med Wochenschr 1996; 126(18): 750–6 PMID8693299